Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
Primary outcomeChange in HbA1c at month 6
Diabetes
Insulin Glargine in Type I Diabetes Mellitus> Main Study "AT.LANTUS": A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar. Sub-study: "HALT"(Hypoglycaemia Avoidance With Lantus Trial)
Primary outcomeMain study: Frequency of severe hypoglycaemia
Diabetes Mellitus, Type 1
The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)
SponsorEli Lilly and Company
Primary outcomeINITIATION: 24-Week Endpoint Glycosylated Hemoglobin (HbA1c)
Diabetes Mellitus, Type 2
Comparison of Insulin Glargine and NPH Human Insulin in Progression of Diabetic Retinopathy in Type 2 Diabetic Patients
Primary outcomeThe percentage of patients with a 3-step or greater progression in the patient
Diabetes Mellitus, Type 2
Insulin Glargine "All to Target" Trial
Primary outcomePercentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0% at Week 60 (Lantus/Apidra-3 Versus Novolog Mix 70/30 - Intent To Treat (ITT) Population Without Good Clinical Practices (GCP) Noncompliant Sites)
Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes
Primary outcomeGlycosylated Haemoglobin A1c (HbA1c)
DiabetesDiabetes Mellitus, Type 2
This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus
Primary outcomeChange From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at Week 26 for the Per Protocol (PP) Population
Diabetes Mellitus, Type 2
Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
Primary outcomePercentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter: Non-inferiority Analysis
Type 1 Diabetes Mellitus
Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes
SponsorEli Lilly and Company
Diabetes Mellitus, Type 2
Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali
SponsorLife for a Child Program, Diabetes Australia
Type 1 Diabetes (T1D)
Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
Primary outcomePercentage of participants with Treatment Emergent Adverse Events (TEAEs)
Type 2 Diabetes Mellitus
The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes
SponsorSun Yat-sen University
Primary outcomeIntergroup remission rate at 24 week
Insulin Pump,Continuous Glucose Monitoring Technology
Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga
SponsorPopulation Health Research Institute
Primary outcomeNumber of Participants Achieving Drug-free Diabetes Remission in the Experimental Group Compared to the Control Group
Type 2 Diabetes Mellitus
Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus
Primary outcomeChange From Baseline to Week 16 in the Percentage of Time in Range [70 to 180 Milligram Per Deciliter (mg/dL)]
Type 2 Diabetes Mellitus
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
Primary outcomePercentage of participants with treatment emergent adverse events (TEAEs) including serious adverse events (SAEs)
Type 2 Diabetes
Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study
Primary outcomeEvaluating the Glycemic control of the regimen : Change in A1C levels
Diabetes Mellitus, Type 1
JanUmet Before Insulin Lantus In Eastern Population Evaluation Program (JUBILEE) In Type 2 Diabetic Patients
SponsorChinese University of Hong Kong
Primary outcomeTo evaluate the treatment efficacy
Type 2 Diabetes Mellitus
Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes
SponsorEli Lilly and Company
Primary outcomeCompare twice-daily insulin lispro Low Mix therapy and once-daily insulin glargine therapy with respect to perceived mood on patient-rated questionnaires following chronic treatment administration in patients with type 2 diabetes
Type 2 Diabetes
Pioglitazone vs. Insulin Glargine in the Treatment of Secondary Drug Failure in Type 2 Diabetes
SponsorSkane University Hospital
Primary outcomeEffect of pioglitazone vs. insulin glargine on beta-cell function and insulin sensitivity
Type 2 DiabetesSecondary Drug Failure
Basal Bolus vs. Sliding Scale for Treatment of Diabetic Patients in Medical Wards
SponsorHaEmek Medical Center, Israel
Diabetes Mellitus Type 2
Lantus Effect on Myocardial Glucose Metabolism in T2
Primary outcomeeffect of insulin treatment on myocardial function, perfusion and glucose metabolism.
Diabetes Mellitus, Type 2
Type 2 Diabetes Management With Lantus® (Malbec: Manejo Con Lantus® de Diabéticos Tipo 2)
Primary outcomeMean difference in HbA1c (efficacy)
Type 2 Diabetes
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Primary outcomeTime From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke
DiabetesDiabetes Mellitus, Type 2
Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM
Primary outcomeChange in HbA1c From Baseline to Week 30
Type 2 Diabetes
A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.
Primary outcomeAbsolute change from baseline in HbA1c
Diabetes Mellitus Type 2
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
SponsorMerck Sharp & Dohme LLC
Primary outcomeChange From Baseline in Hemoglobin A1C at Week 54
Type 2 Diabetes Mellitus
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
SponsorMerck Sharp & Dohme LLC
Primary outcomeChange From Baseline in A1C at Week 30
Type 2 Diabetes Mellitus
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
SponsorGan and Lee Pharmaceuticals, USA
Primary outcomeTreatment-induced Anti-Insulin Antibody (TI-AIA) is the Primary Endpoint
Diabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
Primary outcomeChange From Baseline in HbA1c (Glycosylated Haemoglobin)
DiabetesDiabetes Mellitus, Type 2
Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes
SponsorEli Lilly and Company
Primary outcomeTo compare in patients who at study entry have type 2 diabetes not optimally controlled by one or more oral antihyperglycemic medications plus once daily insulin glargine, a regimen that may include mealtime AIR Insulin.
Diabetes Mellitus, Type 2
Comparison of NN5401 Versus Insulin Glargine, Both Combined With Metformin Treatment, in Subjects With Type 2 Diabetes
Primary outcomeMain Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 26 Weeks of Treatment
DiabetesDiabetes Mellitus, Type 2
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan
Primary outcomeChange from baseline in HbA1c
Type 2 Diabetes Mellitus
Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine
Primary outcomeChange in HbA1c From Baseline to Week 26
Type 2 Diabetes Mellitus
Comparison of the Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Patients With Type 2 Diabetes Insufficiently Controlled on Basal Insulin
Primary outcomeChange in HbA1c
Type 2 Diabetes Mellitus
Insulin Glargine Combination Therapies in Type II Diabetics
Primary outcomeFrequency of subjects with HbA1c ≤ 7.0 % and > 7.0 %
Diabetes Mellitus, Type 2
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus
SponsorEli Lilly and Company
Primary outcomeChange From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
Type 2 Diabetes Mellitus
Comparison of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart in Type 2 Diabetes
DiabetesDiabetes Mellitus, Type 2
Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents
Primary outcomeChange From Baseline in Glycated Hemoglobin (HbA1c) at Week 26
Type 2 Diabetes Mellitus
Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment
Primary outcomeTo determine the difference in glycemic control as measured by HbA1C between substituting the TZD with insulin glargine and adding a third oral agent in patients who fail a TZD/sulfonylurea or TZD/metformin combination therapy
Diabetes Mellitus
Evaluate the Efficacy and Safety of Insulin Compared to Glargine in Patients With Type 2 Diabetes
SponsorEli Lilly and Company
Primary outcomeCompare, in insulin-naive patients with type 2 diabetes on one or more oral antihyperglycemic medications, a regimen adding mealtime HIIP versus a regimen adding insulin glargine with respect to change in HbA1c from baseline to endpoint.
Diabetes Mellitus, Type 2
20 Week Bridging Study in Type II DM
Primary outcomeTo evaluate safety & efficacy of Insulin glargine ( injection at bedtime, once a day) on the changes of HbA1c.
Diabetes Mellitus Type II
Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon
SponsorMassachusetts General Hospital
Primary outcomeBlood Glucose Area Under the Curve (AUC)
Type 1 DiabetesDawn Phenomenon
Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes
Primary outcomeChange in Glycosylated Haemoglobin (HbA1c)
DiabetesDiabetes Mellitus, Type 1
Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy
Primary outcomeChange in fasting plasma glucose (FPG)
DiabetesDiabetes Mellitus, Type 2
PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients
SponsorGan and Lee Pharmaceuticals, USA
Primary outcomePK endpoint
Diabetes Mellitus, Type 1
A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes
Primary outcomeNumber of treatment-emergent adverse events
Diabetes Mellitus, Type 1Healthy Volunteers
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
Primary outcomeIncidence of adverse events
HealthyDiabetesDiabetes Mellitus, Type 1
A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine
Primary outcomeBGpre-exe - BGminimum,exe, difference between blood glucose concentration before exercise and the minimum blood glucose concentration observed during exercise
DiabetesDiabetes Mellitus, Type 1
A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes
Primary outcomeNumber of treatment-emergent adverse events (AEs)
Diabetes Mellitus, Type 2
A Study to Compare and Measure the Effects of Insulin Peglispro (LY2605541) and Glargine on Meal Time Insulin Requirements
SponsorEli Lilly and Company
Primary outcomePharmacodynamics (PD): Plasma Glucose Area Under the Concentration Curve Zero Through 5 Hours (AUC 0-5h), Above Pre Meal Baseline for Insulin Lispro
Diabetes Mellitus, Type 1
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
SponsorEli Lilly and Company
Primary outcomePharmacodynamics (PD): Average Glucose Infusion Rate From Euglycemic 2-step Hyperinsulinemic Clamp (M-value)
Diabetes Mellitus, Type 2
A Study of Insulin Peglispro and Glargine on Fats in Participants With Type 1 Diabetes
SponsorEli Lilly and Company
Primary outcomeVery Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentrations
Diabetes Mellitus, Type 1
Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens
SponsorThird Affiliated Hospital, Sun Yat-Sen University
Primary outcomeThe incidence of diabetic retinopathy
Diabetic Retinopathy